Celldex Therapeutics Inc (CLDX)
EBITDA Growth
-51.43%
TTM · Period ending:
CLDX EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-51.43%period ending
Latest reported-51.43%period ending
CLDX TTM EBITDA YoY % (25.00% → -51.43%)
Year-over-year change
High-resolution chart · PNG
CLDX ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -68.6883% | |
| -52.6068% | |
| -39.793% | |
| -55.0951% | |
| -32.0099% | |
| -30.2329% | |
| -46.4899% | |
| -26.547% | |
| -28.4938% | |
| -16.1765% | |
| 5.4795% | |
| 20.4819% | |
| 22.619% | |
| 37.6147% | |
| 34.2342% | |
| 27.193% | |
| 32.8% | |
| -1.8692% | |
| 0% | |
| -11.7647% | |
| -34.4086% | |
| -16.3043% | |
| -26.1364% | |
| -14.6067% | |
| 0% | |
| -6.9767% | |
| -3.5294% | |
| -18.6667% | |
| -50% | |
| -38.7097% | |
| -53.0612% | |
| -8.7719% | |
| -5.0847% | |
| 10.9091% | |
| -29.5455% | |
| -51.2821% | |
| -103.8462% | |
| -205.5556% | |
| -414.2857% | |
| -184.7826% | |
| 3.7037% | |
| -157.1429% | |
| 216.6667% | |
| 387.5% | |
| -800% | |
| 0% | |
| 14.2857% | |
| 23.8095% | |
| -400% | |
| -16.6667% | |
| -16.6667% | |
| -5% | |
| 125% | |
| 45.4545% | |
| 25% |